Improving the Patient Financial Experience Throughout the Patient Journey While many healthcare providers believe that improving the patient financial experience is a critical step for their ...

CMS says that the model will increase access for patients which in turn will likely improve their health outcomes, especially in areas of unmet need, such as sickle cell disease. CMS Administrator ...

Vertex Pharmaceuticals and bluebird bio have entered into an agreement with CMS to participate in a new Medicaid payment model for gene-based sickle cell anemia treatments, the agency announced ...

The project team have also consulted with expert health professionals to produce a policy document, highlighting model care of children with sickle cell and thalassaemia at school. This document is ...

Historically, sickle cell anaemia has been widely neglected within its global epicentre of sub-Saharan Africa. More than ...

Sickle cells grow into crescent shapes, instead of the round red blood cells seen in people without the gene New research suggests that the history of sickle-cell disease goes back to a mutation ...

Catch up on all the latest pharma industry news from the past month, from breakthroughs in gene therapy to promising drug ...

Two FDA-approved gene therapies, Lyfgenia and Casgevy, will be offered through an outcomes-based Medicaid model launching in January 2025. The initiative ties payments to treatment effectiveness ...

Though he doesn't remember it, Branden Baptiste had his first sickle cell crisis at age 2. Through elementary school, he was in and out of the hospital with pain episodes, not knowing why.